Kornimate/medical-research-clean huggingface dataset:
study of efficacy and safety of laparoscopic intra-abdominal chemotherapy (pipac) performed in patients with peritoneal carcinomatosis from colorectal, ovarian, gastric cancer and primary peritoneal tumors

Conditions: Peritoneal Carcinomatosis

Summary: single center, open label, phase i-ii, non-randomized, two-cohort, repeated single dose study to explore the feasibility, efficacy, safety, and overall response rate (orr) of oxaliplatin, or cisplatin and doxorubicin when given as a pressurized intraperitoneal chemotherapy (pipac) to patients (men and women) with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and in primary cancers of peritoneum.


Eligibility criteria:
inclusion criteria: * clinical and pathological confirmation of peritoneal carcinomatosis from gastric, colorectal and ovarian cancers or primary peritoneal tumors. * patients aged between 18 and 78 years. * performance status sec. ecog ≤ 2 * disease progression/relapse after at least one line of previous i.v. standard chemotherapy in gastric cancer and primary peritoneal tumors and two lines in colorectal and ovarian cancers. * patients with peritoneal carcinomatosis from ovarian, gastric and colorectal cancers and primary peritoneal cancers not eligible to cytoreductive surgery +/- hipec. * blood and electrolyte counts, liver, renal and cardiopulmonary function parameters within 10% of the normal range. * written informed consent. * tumor mass present on ct-scan in order to allow tumor response assessment with recist-criteria. exclusion criteria: * extra-abdominal metastatic disease, with the exception of isolated pleural carcinomatosis. * bowel obstruction. * severe renal impairment, myelosuppression, severe hepatic impairment, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias. * immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system. * creatinine clearance \< 60 ml /min. * pregnancy. * previous treatment reaching the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin and/or other anthracyclines and anthracenediones. * known allergy to cisplatin or other platinum-containing compounds or to doxorubicin. * patients of both sexes who do not conduct complete abstinence from heterosexual relationships or agree to use an effective clinically acceptable method (with failure rate \<1%) during the study and the following 6 months after the last treatment.

Keywords: pressurized intra peritoneal air-flow chemotherapy (pipac) chemotherapy peritoneal carcinomatosis
effectiveness of physiotherapist's communication skills on clinical outcomes in chronic musculoskeletal patients

Conditions: Chronic Musculoskeletal Pain

Summary: the purpose of this study is to investigate the impact of the physiotherapist's communication on the clinical presentation of patients with chronic musculoskeletal pain.

the purpose of this study is to investigate the impact of the physiotherapist's communication on the clinical presentation of patients with chronic musculoskeletal pain. sixty-nine (69) patients with chronic musculoskeletal pain in the cervical or lumbar spine, knee, or shoulder will participate. they will be randomly divided into three groups, each consisting of thirty-three (33) patients. one group (experimental- good communication skills) will watch the video in which physiotherapist will develop qualities of good communication while he explains about chronic musculoskeletal pain, the other group (experimental- poor communication skills ) will view the video in which the physiotherapist imparts information and explains chronic pain without enhancing his communication skills and lastly, the control group (control) that will not view any video.

Eligibility criteria:
inclusion criteria: * participants should speak and understand the greek language, as the questionnaires and the video will be in greek * participants should experience pain in one of the following four different areas: cervical or lumbar spine, knee, or shoulder * pain of musculoskeletal origin * pain lasting more than 3 months, evident on most days of the week to be classified as chronic pain, with a pain intensity of at least 3/10 numeric pain rating scale. exclusion criteria: * medication for neurological/psychiatric disorders * pain medication on the day agreed upon with the researcher, in order to minimize the potential influence of medication * undergoing surgery in the last six months * pregnancy or childbirth before 1 year

Keywords: communication skills chronic musculoskeletal pain
right ventricular contractile reserve in hf

Conditions: Heart Failure

Summary: right ventricle dysfunction and pulmonary hypertension are related to a worse prognosis in patients with heart failure with reduced left ventricular ejection fraction (hfref) or with normal left ventricular ejection fraction (hfpef). there is preliminary evidence however, that the responses of the right ventricle and of the pulmonary hemodynamics to stress tests (especially physical stress) may allow to prognostically stratify these patients, as these responses may bring out latent right ventricle dysfunction or a normal contractile reserve in patients with dysfunction at rest. in view of the different pathophysiological mechanisms of the left ventricular dysfunction in hfpef and in hfref, also the response and the adaptation of the righty ventricle to stress tests may be different in these two groups of patients. in this preliminary two groups of 20 patients with hfpef and hfref will be subjected to to simple stress tests: passive leg raising and inotropic stimulus with dobutamine. this study intends to analyze, through colordoppler echocardiography, the behaviour of the right ventricle and the pulmonary circulation during passive leg raining and infusion of dobutamine, in a cohort of patients with hfref or hfpef. the analysis will be focused on the relation between echocardiographic parameters, especially those concerning right ventricular function and pulmonary hemodynamics, thereby comparing the responses observed in hfref vs hfpef. furthermore, correlations between the above-mentioned echocardiographic parameters and parameters of daily clinical practice will be assessed.


Eligibility criteria:
inclusion criteria: * heart failure with reduced (ef ≤40%) or preserved (ef \> 50%) ejection fraction * echocardiographic acoustic window adequate for evaluation of outcome parameters * presence of tricuspid insufficiency which allows assessment of pulmonary artery systolic pressure exclusion criteria: * recent myocardial infraction (\<3 months) or unstable angina * moderate o severe aortic or mitralic valve disease * inadequate acoustic window * significant anemia (hemoglobin \<10 g/dl) * recent heart surgery (\< 3 months).
comparison between connective graft and xenogeneic matrix, in patients with multiple gingival recessions

Conditions: Gingival Recession, Generalized

Summary: subepithelial connective tissue graft (sctg) is considered the gold standard for root coverage treatment. however, it is associated with postoperative morbidity, limited amount of donor tissue, and longer surgical time. thus, the search for a tissue substitute for sctg is increasing. currently, one of the possible autogenous soft tissue substitutes found in the market is the mucograft® xenogeneic matrix (cm). the results with the use of mc are very promising, both for root coverage as well as for the gain of keratinized tissue. the present study consists of a parallel randomized clinical trial to compare sctg (control group) and cm (test group) in the treatment of miller's class i and ii gingival recessions, multiple in aesthetic areas (upper central incisors, lateral and canine).

obtaining an aesthetic smile is one of the main reasons for the patient's demand for dental treatment, especially when it comes to gingival recession. however, there is a lack of evidence in the literature explaining the most appropriate type of treatment for multiple recessions in aesthetic areas. for unitary gingival recessions, the subepithelial connective tissue graft (sctg) is considered the gold standard because it presents greater predictability for root coverage. however, it is associated with postoperative morbidity, limited amount of donor tissue, and longer surgical time. thus, the search for a tissue substitute for sctg is increasing. currently, one of the possible autogenous soft tissue substitutes found in the market is the mucograft® xenogeneic matrix (cm). the results with the use of cm are very promising, both for root coverage as well as for the gain of keratinized mucosa. the present study will consist of a double-blind parallel randomized clinical trial to compare sctg (control group) and cm (test group) in the treatment of miller's class i and ii gingival recessions, multiple in aesthetic areas (central incisors, lateral, upper canine). all measurements will be evaluated initially and in the periods of 3, 6, and 12 months after the surgical procedure.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of multiple gingival recessions ≥ 2 mm, only in aesthetic areas (upper central and lateral incisive, and canine); * miller class i and ii gingival recession areas * non-abrasive, erosive, or carious root surfaces * unrotated, non-extruded, and non-movable teeth * systemically healthy patients without contraindication to periodontal surgical procedures exclusion criteria: * smokers * pregnant women and infants * patients with a history of periodontal disease or recurrent abscess formation * patients previously submitted to surgical procedures for root coverage * patients taking anti-convulsant drugs * antihypertensives, contraceptives or immunosuppressors * patients with low oral hygiene (plaque and bleeding index over 20%)

Keywords: gingival recession collagen matrix periodontics
diagnostic evaluation study of the bactinsight blood culture system in west-africa

Conditions: Bacterial Infections

Summary: diagnosis of bloodstream infections (bsi) is done by sampling blood in blood culture bottles that are checked for growth in the microbiology laboratory. in lrs, microbiology laboratories are however scarce, and bsi cannot be diagnosed, resulting in overuse of antibiotics which fuels amr. for diagnosis of bsi, so-called manual blood culture (equipment-free) systems are used in lrs, with daily visual inspection for growth. compared to automates, manual systems are less sensitive, and growth is slower; in addition, training and experience are needed before laboratory staff is competent to detect growth when inspecting the blood culture bottles. a simplified blood culture system could enable expanded use of blood cultures in lrs and would thus improve bsi treatment. ongoing research at the institute of tropical medicine, in collaboration with ghent university has resulted in a novel, simple, cheap, open-access and robust blood culture system, the bactinsight blood culture system. this system consists of two modules. firstly, a portable, battery-operated measurement device (turbidimeter), which monitors and detects bacterial growth in blood culture bottles based on the turbidity of the culture medium caused by bacterial growth. secondly, optimized blood culture bottles have been developed. a second step in blood cultures is the identification of the causing organism. researchers at leti (grenoble, france) have developed a lensfree microscope, which simplifies and expedites identification of the causative organisms, improving patient's diagnosis and more directed antibiotic treatment. the lensfree microscope is an additional module for the bactinsight blood culture system. in simble, the bactinsight blood culture system will be evaluated against reference systems in two phases. during the optimization phase in belgium, the performance of bactinsight turbidimeter + lensfree microscope will be tested in a reference hospital laboratory. in parallel, an in vitro laboratory evaluation of the bactinsight blood culture system (turbidimeter + blood culture bottles + lensfree microscope) will be done using spiked blood cultures. in the field-testing phase, the ease-of-use, acceptability, adoptability and performance of bactinsight blood culture system will be evaluated in three hospitals in benin and burkina faso. the blood culture bottles used for this study will be manufactured in a production facility in benin, that will be installed at the start of the project.


Eligibility criteria:
inclusion criteria: * with indications for blood culture sampling and for whom collection of a blood culture sample is part of standard clinical practice * willing and able to provide written informed consent (assent for minors) exclusion criteria: * none

Keywords: blood culture diagnostics
effect of vitamin d supplementation on the efficacy of ustekinumab in the treatment of crohn's disease

Conditions: Ustekinumab; Vitamin D Supplementation; Crohn's Disease; Clinical Efficacy

Summary: it is uncertain whether vitd3 supplementation is beneficial for the remission of crohn's disease (cd). the effects of vitd3 supplements on the efficacy of ustekinumab in chinese cd patients were retrospectively analyzed. methods: patients with moderate to severe cd were recorded. these patients were initially treated with ust. vitd3 supplementation was defined as 400iu/d vitd3 supplementation during the first infusion of ust and continued throughout the follow-up period. disease activity was assessed using harvey bradshaw index.


Eligibility criteria:
inclusion criteria: * moderate-to-severe cd * treated with ustekinumab exclusion criteria: * had recent supplementation of vitd3 * pregnant * had cognitive/developmental disorders that affected their ability to complete the study procedures * had medical illness or therapies potentially affecting bone, nutrition or growth status * unknown or untested baseline serum 25(oh)d level
non transplantable recurrence after percutaneous thermal ablation of hcc

Conditions: HCC

Summary: percutaneous thermal ablation (pta), resection and liver transplantation (lt) are the standard curative options for hepatocellular carcinoma (hcc). lt yields the best long-term outcomes but is limited by graft shortage. thus, patients with ≤3cm hcc are mainly treated by pta although recurrence is frequent and may occur outside transplant criteria. however, data on non transplantable recurrence (ntr) following pta are lacking. therefore, the investigators investigated the incidence and predictors of ntr among transplantable patients with ≤3cm hcc(s) treated by pta, in order to stratify them according to their ntr risk and to improve treatment allocation.

consecutive patients undergoing pta for hcc between january 2015 and december 2020 were included. data were collected from our prospective database. this study was approved by our institutional review board (nct03428321 \[www.clinicaltrials.gov\]) and written informed consent was obtained from all patients. inclusion criteria were: hcc diagnosed by histopathology or by easl imaging criteria, hcc ≤30mm, 1 - 3 tumor nodules, follow-up\<3 months, no prior or combined treatment with intra-arterial therapy, potentially transplantable patient (ie, ≤70yr, afp-score≤2 (7), no macroscopic portal vein invasion or extra-hepatic metastasis, no major comorbidity precluding lt). patient's and liver's characteristics were collected including: age, sex, hcc-naïve status, body mass index (bmi), diabetes mellitus, liver steatosis, cirrhosis, cause for hepatopathy, afp serum level, child-pugh, meld and albumin-bilirubin (albi) scores and preablative biological data. occurrence of ntr after pta will be analyzed in a competing risks framework, with transplantation and death as competing events. covariates associated with ntr were analyzed using fine-gray proportional sub-distribution hazards models. recurrence-free survival (rfs) will be defined as the time from pta until the first recurrence, death, or last follow-up. os will be defined as the interval between pta and death (any cause) or last follow-up. survival curves will be estimated using the kaplan-meier method and compared with the log-rank test.

Eligibility criteria:
inclusion criteria : * hcc diagnosed by histopathology or by easl imaging criteria * hcc ≤30mm, 1 - 3 tumor nodules, follow-up\<3 months * no prior or combined treatment with intra-arterial therapy * potentially transplantable patient (ie, ≤70yr, afp-score≤2 (7), no macroscopic portal vein invasion or extra-hepatic metastasis, no major comorbidity precluding lt). exclusion criteria: - age \< 18 years

Keywords: with or without cirrhosis bclc0 or a no extra-hepatic disease radiofrequency ablation microwave ablation liver transplantation
conjoined twins: a report of four cases.

Conditions: Conjoined Twin

Summary: the present study aims to report our experience in conjoined twin separation surgery in assuit university and pediatric hospital, assiut university, assiut, egypt over a period of 20 years.

a conjoined twin is a subset of monozygotic twin gestation. it's a rare phenomenon with an incidence of 1 in 50,000 to 1:100,000 births with the higher incidence in africa and southwest asia. based on the terminology proposed by spencer and colleagues, conjoined twins are classified according to the most prominent site of conjunction into three major groups; first, twins with a ventral union; \[cephalopagus (head), thoracopagus (thorax), omphalopagus (abdomen) and ischiopagus (pelvis)\]. second; twins with a dorsal union; \[pygopagus (sacrum), rachipagus (spine, back) and craniopagus (cranium)\] and lastly; twins with a lateral union that is referred to as parapagus (side). depending on the aspect of the embryonic disc, the most common types are thoracopagus (19%). surgical separation of conjoined twins is extremely challenging taking in consideration the high perioperative risk. the low incidence of such surgeries and anatomical variations in each type of conjoined twins makes each separation surgery a unique experience.

Eligibility criteria:
inclusion criteria: * conjoined twins * symmetrical or * asymmetrical. exclusion criteria: * conjoined twins incompatible with life * conjoined twins with decapitating medical illness.
automated telephone monitoring for symptom management

Conditions: Carcinoma

Summary: to improve the management of symptoms, patients with cancer undergoing chemotherapy will be monitored using an automated telephone system to record the severity of 15 prevalent symptoms for up to 8 consecutive weeks. outcomes include; significant reduction in symptom severity and improvement in health states.

overview: prevalent symptoms among patients undergoing chemotherapy include: pain, fatigue, dry mouth, constipation, anorexia, nausea, sleep disturbance, shortness of breath or difficulty breathing, as well as psychological symptoms such as depression and anxiety. a survey of 1000 patients with cancer indicated that close to a quarter reported 10-12 symptoms. given the impact of symptoms upon physical function, work, emotional distress, and hospitalizations, it is critical that strategies be developed and tested to improve symptom management. this trial of a behavioural intervention for symptom management is significant because: 1) it contrasts a proactive approach, individualized to patients' symptom management needs, with a more conventional model that places responsibility on the patient for symptom management; 2) it controls for the method of delivery and the use of printed material; 3) it targets prevalent symptoms known to affect cancer patients undergoing chemotherapy; 4) it examines the relative effects of each arm, in terms of symptom severity (primary outcome), impact on patients' physical and social roles, and emotional distress; and 5) it explores these outcomes in terms of their impact on the use of services and costs of care. goal: the goal of this randomized trial is to determine if a nurse delivered patient assisted management of symptoms (pams) intervention individualized to patients' needs for symptom management, delivered by telephone, when compared to telephone information and monitoring of symptoms (tims) where symptoms are only monitored by telephone, with references to the symptom management toolkit will reduce symptom severity, improve physical function, and other outcomes.

Eligibility criteria:
inclusion criteria: * 21 years of age or older * solid tumor cancer diagnosis * receiving chemotherapy treatment exclusion criteria: * emotional or psychology disorder for which patient is receiving treatment * does not speak english * does not have access to a telephone * difficulty hearing on the telephone

Keywords: symptom management cancer chemotherapy treatment behavioral research physiological effects of drugs clinical trial, phase ii
use of concomitant medications in hiv-1 infected patients in a large community practice in sydney, australia

Conditions: HIV

Summary: for the majority of patients, management of hiv-1 infection involves effective and well tolerated antiretroviral therapy with simplified pill load and dosing, exemplified by the availability of single tablet regimens (strs) with single tablet once daily dosing. str therapy has been shown to improve adherence and reduce hospitalisations (cohen et al., 2013; sax et al., 2012). however, the aging of the hiv cohort in australia and globally has raised issues of increasing co-morbidities and consequent polypharmacy to manage these (jansson \& wilson, 2012; edelman et al., 2013). polypharmacy may not only impact on adherence, but also increases the potential for drug-drug interactions (holtzman et al., 2013). stribild, a highly effective str, contains cobicistat to boost the levels of the component integrase inhibitor, elvitegravir. cobicistat does not have antiretroviral activity, but acts by inhibiting cyp3a4 of the cytochrome p450 metabolic pathway. other drugs metabolized via this pathway may be affected by this drug-drug interaction (rogatto et al., 2014). additionally there is evidence of increased risk of nephrotoxicity with co-administration of tenofovir and non-steroidal anti-inflammatory medication (nsaids) (marcotte et al., 2008). data on use of concomitant medications in australian patients with hiv is sparse. this study aims to determine, in a large caseload community hiv practice, the use of concomitant medications in hiv, patient pill load and dosing frequency, and potential drug-drug interactions with stribild.


Eligibility criteria:
inclusion criteria: * documented hiv-1 infection * attendance during the study period for at least 2 visits \>3 months and \<12 months apart with measured laboratory virological or immunological markers (either on-site or at a co-management site). exclusion criteria: * attendance by patient with hiv infection who does not have laboratory markers of hiv viral load or cd4 count * incomplete/inaccessible patient records

Keywords: polypharmacy medication therapy management
a prospective comparison between ureteral stent and nephrostomy tube for an urgent drainage of obstructed kidney

Conditions: Kidney Disease

Summary: kidney obstruction might be caused by a stone in the urinary tract. in case of accompanying fever or renal failure, an urgent drainage might be needed. this can be done either by placing an ureteral stent or a nephrotomy tube. only limited number of studies examined the question which of the two is preferred. a debate exist regarding the effectiveness of each procedure to improve symptoms, renal function and treating an infection. our goal is to resolve this debate and to state whether one way is preferred on the other.


Eligibility criteria:
inclusion criteria: patient suffering from obstructed kidney by a stone and at least one of these situations: 1. fever (above 38c) 2. a rise in creatine to above 1.5 3. pain resistent to multiple analgetic treatments exclusion criteria: * patients with medical condition that prevent the use of one of the procedures

Keywords: preferred procedure drainage obstructed kidney stone